Compare Smith & Nephew plc (SNN) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Wix.Com Ltd — how do they compare? Smith & Nephew plc trades at $27.72 (market cap $11.63B), while Wix.Com Ltd trades at $73.87 (market cap $3.04B). The key difference: Smith & Nephew plc is far larger — about 3.8× Wix.Com Ltd's market cap, and Smith & Nephew plc pays a 2.85% dividend while Wix.Com Ltd pays none. Which is the better fit depends on your goals.
| SNN | WIX | |
|---|---|---|
Market Cap | $11.63B | $3.04B |
Sector | Health | Technology |
52-Week High | $38.53 | $184.24 |
52-Week Low | $27.80 | $40.43 |
Enterprise Value | $14.66B | $4.12B |
Dividend Yield | 2.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
WIX trades at $72.72, down 4.58% in the last session, with a bearish technical signal and negative net cash flow of -$344.06M in 2025. Revenue grew to $1.99B in 2025, but net income margin remains negative at -8.19% for 2026. The stock faces multiple class action lawsuits alleging securities fraud, with a deadline of September 22, 2026, adding legal overhangs.
The outlook is mixed: analyst consensus is a Buy with a $73.36 target, near the current price, but risks from litigation and volatile earnings pose headwinds. Investment opportunity hinges on execution amid competitive pressures, while downside protection is limited by weak profitability and negative shareholder equity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
